By Kura Oncology | September 11, 2017Kura Oncology Presents Positive Phase II Results Tipifarnib in HRAS Mutant Head and Neck Cancer
By Kura Oncology | July 18, 2017Kura Oncology Establishes Collaboration With Foundation Medicine to Support Tipifarnib Development
